Report
Cancer trial drug zavondemstat reportedly largely blocks DHODH rather than KDM4
Medical Xpress says the unexpected target mismatch may have implications for the drug’s ongoing clinical development.
TLDR
Medical Xpress reports that zavondemstat, a drug in cancer trials, largely blocks DHODH rather than its expected target, KDM4. The outlet says the mismatch may have implications for its ongoing clinical development.
Combined views
1.4K
2 Sources, first seen ago
6 likes2 saves3 reposts